About Pharmapark

The founder of PharmaPark has invented a novel approach to obtain medicines against disabling and lethal diseases like Children’s leukaemia.

Because early medicine development is commercially challenging, the PharmaPark Foundation was established in 2004 to maximize a stable development of important medicines for these diseases.

It is the aim of PharmaPark to promote generation of new medicines against important diseases such as Children’s leukaemia, other forms of cancer and immune related therapies (for instance against Asthma or Arthritis).

PharmaPark operates by acting as a Holding company for IP and by assisting companies in finding new partners the generation of medicines that make a substantial difference.